Program
batoclimab
Also written as “Batoclimab”, “Batoclimab 340 mg SC weekly” and “HBM9161 Injection (680mg)”.
Its studies are mostly in Graves Ophthalmopathy · Myasthenia Gravis · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Graves Disease · Purpura, Thrombocytopenic, Idiopathic, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Immunovant Sciences | 110 open or running | phase 3since May 26, 2022 | Feb 20, 2019 | none ahead |
| Harbour BioMed (Guangzhou) | 70 open or running | phase 3since Jun 9, 2020 | May 30, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Feb 20, 2019.
- Apr 17, 2019Phase 2 study in Graves OphthalmopathyImmunovant Sciences · NCT03922321 · 7 enrolled · Canada
- May 1, 2019Phase 2 study in Graves OphthalmopathyImmunovant Sciences · NCT03938545 · 65 enrolled · United States, Canada, Germany and more
- May 30, 2019Harbour BioMed (Guangzhou)'s first study: phase 1 study in Healthy Chinese VolunteersNew to Harbour BioMed (Guangzhou)Harbour BioMed (Guangzhou) · NCT03971916 · 24 enrolled · China
- Nov 21, 2019Phase 1 study in Neuromyelitis OpticaHarbour BioMed (Guangzhou) · NCT04227470 · 9 enrolled · China
- Jan 21, 2020Phase 2 study in Warm Autoimmune Hemolytic AnemiaImmunovant Sciences · NCT04253236 · 5 enrolled · United States, Israel, Korea, Republic of and more
- Apr 13, 2020Phase 2 study in Myasthenia GravisHarbour BioMed (Guangzhou) · NCT04346888 · 30 enrolled · China
- Jun 9, 2020Phase 3 study in Primary Immune Thrombocytopenic PurpuraHarbour BioMed (Guangzhou) · NCT04428255 · 36 enrolled · China
- Aug 3, 20212 phase 3 studiesHarbour BioMed (Guangzhou) · NCT05015127, NCT05039190
- Apr 6, 2022Phase 3 study in Myasthenia GravisHarbour BioMed (Guangzhou) · NCT05332210 · 111 enrolled · China
- May 26, 2022Phase 3 study in Myasthenia GravisImmunovant Sciences · NCT05403541 · 233 enrolled · United States, Argentina, Brazil and more
- Aug 24, 20223 phase 3 studies in Graves OphthalmopathyImmunovant Sciences · NCT05524571, NCT05517447, NCT05517421
- Oct 12, 2022Phase 2 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingImmunovant Sciences · NCT05581199 · 94 enrolled · United States, Argentina, Belgium and more
- May 15, 2023Phase 2 study in Graves DiseaseImmunovant Sciences · NCT05907668 · 32 enrolled · Germany
- Sep 16, 2025Phase 2 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingImmunovant Sciences · NCT07188844 · 26 enrolled · United States, Argentina, Belgium and more
TargetBeta
“IgG receptor FcRn large subunit p51 inhibitor”ChEMBL 37, by rule
Other programs on FCGRT
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| efgartigimod alfarule | argenx | phase 4 | 48 |
| rozanolixizumabrule | UCB | phase 4 | 23 |
| nipocalimabrule | Johnson & Johnson | phase 3 | 24 |
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07188844Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Belgium and more | 2 | Terminated | Immunovant Sciences | Jul 16, 2026 | 26 |
| NCT05907668Graves Disease · Germany | 2 | Completed | Immunovant Sciences | Jul 25, 2025 | 32 |
| NCT05581199Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Belgium and more | 2 | Terminated | Immunovant Sciences | Jul 20, 2026 | 94 |
| NCT05524571Graves Ophthalmopathy · United States, Australia, Belgium and more | 3 | Completed | Immunovant Sciences | Feb 3, 2026 | 86 |
| NCT05517447Graves Ophthalmopathy · United States, Australia, Belgium and more | 3 | Terminated | Immunovant Sciences | Apr 2, 2026 | 109 |
| NCT05517421Graves Ophthalmopathy · United States, Canada, Georgia and more | 3 | Completed | Immunovant Sciences | Nov 2, 2025 | 114 |
| NCT05403541Myasthenia Gravis · United States, Argentina, Brazil and more | 3 | Terminated | Immunovant Sciences | Jan 10, 2025 | 233 |
| NCT05332210Myasthenia Gravis · China | 3 | Completed | Harbour BioMed (Guangzhou) | Apr 26, 2024 | 111 |
| NCT05039190Myasthenia Gravis · China | 3 | Completed | Harbour BioMed (Guangzhou) | Jan 14, 2023 | 132 |
| NCT05015127Graves Ophthalmopathy · China | 3 | UNKNOWN | Harbour BioMed (Guangzhou) | Oct 2022 | 36 |
| NCT04428255Primary Immune Thrombocytopenic Purpura · China | 3 | Completed | Harbour BioMed (Guangzhou) | Aug 10, 2021 | 36 |
| NCT04346888Myasthenia Gravis · China | 2 | Completed | Harbour BioMed (Guangzhou) | Aug 24, 2021 | 30 |
| NCT04253236Warm Autoimmune Hemolytic Anemia · United States, Israel, Korea, Republic of and more | 2 | Terminated | Immunovant Sciences | Apr 1, 2021 | 5 |
| NCT04227470Neuromyelitis Optica · China | 1 | Completed | Harbour BioMed (Guangzhou) | Dec 3, 2021 | 9 |
| NCT03971916Healthy Chinese Volunteers · China | 1 | Completed | Harbour BioMed (Guangzhou) | Nov 6, 2019 | 24 |
| NCT03938545Graves Ophthalmopathy · United States, Canada, Germany and more | 2 | Terminated | Immunovant Sciences | Feb 2, 2021 | 65 |
| NCT03922321Graves Ophthalmopathy · Canada | 2 | Completed | Immunovant Sciences | Feb 29, 2020 | 7 |
| NCT03863080Myasthenia Gravis · United States, Canada | 2 | Completed | Immunovant Sciences | Oct 7, 2020 | 17 |
How it is read
Names in the registry
- “Batoclimab”, 4 entries
- “Batoclimab 340 mg SC weekly”, 2 entries
- “HBM9161 Injection (680mg)”, 2 entries
- “RVT-1401”, 2 entries
- “Batoclimab 680 mg SC weekly”, 1 entry
Conditions, from the studies’ own filings
- Graves Ophthalmopathy, 6 studies
- Myasthenia Gravis, 5 studies
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, 2 studies
- Graves Disease, 1 study
- Purpura, Thrombocytopenic, Idiopathic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.